Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug

Spyre Therapeutics stock jumps after Phase 2 SKYLINE data; SPY001 shows efficacy in ulcerative colitis as analysts maintain bullish outlook. Importance Rank: 1 read more

Go to News Site